BioSniper
Phase 2 Start~month

Phase 2 Start: An Open-label, Multi-center, Phase I/II Study of ERW316 as a Single Agent or in Combination With End

June 30, 2026
Company
Novartis AG (NVS)
Drug
erw316
Indication
Metastatic Castration-resistant Prostate Cancer (mCRPC); Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors

Other upcoming events for NVS

Phase 1 StartPhase 1 Start: A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate
Jun 23, 2026
Phase 2 StartPhase 2 Start: NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R
Jun 29, 2026
Phase 2 StartPhase 2 Start: A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Ch
Jun 30, 2026
Phase 3 ReadoutPhase 3 Topline: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein
Jun 30, 2026
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
Jul 15, 2026

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
NVS OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle